Cell and gene therapy (CGT) products are complex biologic medicines that often require specialized, more resource-intensive patient care, close monitoring, and longitudinal follow-up. As such, early CGT delivery in the United States (U.S.) was highly centralized in academic centers, reflecting the need for dedicated infrastructure, clinical expertise, and tight operational control.

This model limited patient access by creating additional burdens for patients and providers. However, CGT delivery is evolving as market experience grows, clinical evidence matures, regulators ease certain requirements, and the treatment network expands beyond early academic hubs. This whitepaper, co-authored by ARM and Guidehouse, leverages U.S. claims data on select CGT products to examine the evolution of CGT delivery beyond the early academic-focused model.

If you have any questions about the whitepaper and its contents, please reach out to the contacts below.

ARM: [email protected]

Guidehouse: [email protected]